Home
Smart & Biggar
Urszula Wojtyra
Urszula Wojtyra
Smart & Biggar
Federal Court Approves Litigation Funding Agreement In Proposed Class Proceeding Against Generic Drug Manufacturers
02 Oct 2021 | Canada
PM(NOC) Regulations: Fourth Year Following Major Amendments
02 Oct 2021 | Canada
Quebec Initiating A Shift To Use Of Biosimilar Drugs
19 Jul 2021 | Canada
Amendments To Food And Drug Regulations (Exports), Natural Health Products Regulations (Labelling)
16 Jul 2021 | Canada
Federal Court Dismisses Roche's PMNOC Regulations Actions Against Sandoz Re: Pirfenidone
02 Jul 2021 | Canada
Federal Court Of Appeal Finds Summary Trial Appropriate, Upholds Dismissal Of ViiV's Action For Patent Infringement Re: Gilead's BIKTARVY
02 Jul 2021 | Canada
Update On Biosimilars In Canada - April 2021
04 Jun 2021 | Canada
Federal Court Reinstates Decision That REMICADE New Use Patent Is Valid And Infringed
26 Feb 2021 | Canada
Supreme Court Of Canada Leave Applications – January 2021
02 Feb 2021 | Canada
Strict 45-Day Time Limit For Starting PMNOC Action Was Suspended By COVID-19 Federal Legislation
23 Dec 2020 | Canada
Federal Court Of Appeal Dismisses Appeal Of First Trial Decision Under The Amended PMNOC Regulations
02 Dec 2020 | Canada
New Federal Court Guidelines For Complex Proceedings Consolidate And Update Previous Guidelines
02 Dec 2020 | Canada
Federal Court Orders Minister Of Health To Issue NOC To Fresenius Kabi For Its Biosimilar IDACIO Following Filing Of Consent Letter
10 Nov 2020 | Canada
Amended PM(NOC) Regulations: Third Anniversary Update
01 Oct 2020 | Canada
Update On Biosimilars In Canada – August 2020
28 Aug 2020 | Canada
On Redetermination, PMPRB Concludes That Galderma's Patent ‘pertains To' DIFFERIN
07 Aug 2020 | Canada
Proposed Class Action Alleges Generic Manufacturers Conspired To Price-fix And Allocate Generic Market
29 Jun 2020 | Canada
PMPRB Releases Three New NPDUIS Reports
10 Jun 2020 | Canada
Federal Court Of Appeal Sets Aside Order For Common Trial Across Multiple Actions Under PMNOC Regulations
10 Jun 2020 | Canada
First Decision Under Amended PMNOC Regulations: Federal Court Finds Amgen's Filgrastim Patent Obvious
28 May 2020 | Canada
< 1 2 3 >
20%
Very Popular: This author falls within the Top 20% for the below topics and industry categories
Based on Mondaq users readership, this author is ranked as VERY POPULAR in Canada for the topics, user groups and industry sectors listed below*:
Topics
  • Intellectual Property
  • Patent
  • Court Procedure
  • Litigation, Mediation & Arbitration
  • Trials &amp; Appeals &amp; Compensation
  • Food and Drugs Law
Industry
  • Pharmaceuticals & BioTech
* Rankings are based on analysis of the last 12 months of Mondaq readership data across more than 25,000 contributing authors. To be ranked ‘Very Popular’ an author must be in the top 20% of results within the selected criteria.
Contact Details
Toronto
Email Website
1100-150 York Street
Toronto
Canada
Telephone: 1-613-2322486

  © Mondaq® Ltd 1994 - 2021. All Rights Reserved.